Stable Istotope Labelled Reslizumab Biosimilar – Anti-IL5 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Istotope Labelled Reslizumab Biosimilar - Anti-IL5 mAb - Research Grade |
|---|---|
| Source | CAS 241473-69-8 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >95% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue Ice |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | CDP-835,JES1-39D10,SCH55700 |
| Reference | PX-TA1198-SIL |
| Related Products | PX-P4558 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG4-nd |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
General information on Anti-IL5(Homo sapiens) (Reslizumab) Monoclonal Antibody
Reslizumab is a humanized interleukin 5 (IL-5) antagonist monoclonal antibody (IgG4 kappa), produced by recombinant DNA technology in murine non-secretory myeloma 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophil markers. Elevated levels of eosinophils increase the risk of exacerbation of asthma, including allergic and non-allergic forms of asthma characterized by eosinophilia. By targeting IL-5 and disrupting its signaling pathway, reslizumab aims to inhibit the maturation of eosinophils and promote programmed cell death. Reslizumab is sold as Cinqaero in Europe.
Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.